#USA #Neuronetics #Bloomfield Hills #TMS Business #Jorey Chernett

Jorey Chernett's Vision for Neuronetics, Inc.

In a bold move that could reshape the landscape of Neuronetics, Inc., Jorey Chernett, the company's largest independent shareholder with a 14.12% stake, has put forth a compelling case for the immediate review of strategic alternatives. In a recent letter directed to the Board of Directors, Chernett urged them to consider various options, including the potential sale of the company's Transcranial Magnetic Stimulation (TMS) business.

The Market Context

The TMS business, which focuses on innovative treatments for mental health conditions, has a promising market potential. Chernett's proposal emerges in the wake of the December 2024 acquisition of Greenbrook TMS, which was expected to yield synergies and elevate the company's performance. However, despite these high hopes, Chernett has noted that the anticipated benefits have not materialized. Instead, market performance indicates that its pure-play peers are outpacing Neuronetics, trading at significantly higher multiples, showcasing their strategic agility.

A Case for Strategic Alternatives

In his letter, Chernett emphasizes the advantages of a thorough review of the company's assets, namely that it holds two high-quality, compelling businesses. These include not only the TMS side but also the standalone clinic operations. Here are some key points he made:

• - Two Distinct Businesses: The TMS and clinic businesses serve different market segments. A micro-cap company like Neuronetics may struggle to manage resources effectively across both segments.
• - Potential Shareholder Value Increase: Chernett claims that applying reasonable market multiples to each business could result in shareholder equity values that are 5 to 7 times the current trading price of Neuronetics’ stock. This highlights the latent value present within the assets.
• - Need for Focused Efforts: With a dedicated management approach for the clinic business, further value may be unlocked, benefiting shareholders and patients alike.

The essence of Chernett's message is clear: it’s imperative for the board to act in the best interest of shareholders and engage qualified advisors to explore strategic pathways that could include divesting the TMS business.

The Path Forward

Moving ahead, it will be crucial for Neuronetics' leadership to weigh Chernett’s insights carefully. Engaging with shareholders and exploring these strategic options can potentially lead to enhancements in operational effectiveness and increased shareholder return. As the market landscape continues to evolve rapidly, stakeholders will be watching closely to see how the company responds to this call for action.

Chernett’s willingness to speak out on these matters exemplifies a growing trend among investors who seek greater returns and strategic realignment within companies they have stakes in. For Neuronetics, this moment could represent a pivotal turn towards maximizing its inherent asset value, potentially setting a precedent for others in the industry.

As the dialogue unfolds, the focus will remain on the board's response and their commitment to ensuring that shareholder interests are prioritized as Neuronetics navigates these challenging waters. The conversation started by Chernett could very well be the catalyst for significant future developments at Neuronetics, Inc.